Scott Byrd, Sudo Biosciences CEO (Frazier Healthcare Partners)
September 28, 2022 08:00 AM EDTUpdated 08:10 AM
Financing
Startups

Bris­tol My­ers got the first TYK2 ap­proval. Fra­zier’s new biotech Su­do hopes to get many more

Lei Lei Wu

News Reporter

Ear­li­er in Sep­tem­ber, the FDA ap­proved a TYK2 in­hibitor for the first time, a drug from Bris­tol My­ers Squibb for pso­ri­a­sis, with­out slap­ping on the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Up­dat­ed: No­vo Nordisk CEO to step down amid stock de­cline, time­line for suc­ces­sor un­known

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

FDA pos­es ef­fi­ca­cy, safe­ty ques­tions over four can­cer drugs ahead of two-day ad­comm

No­vo Nordisk’s glob­al obe­si­ty leader is mov­ing on; Flag­ship biotech gets CEO from Schol­ar Rock

'Go ahead and do it': Top RFK Jr. deputy dares drug­mak­ers that might pull man­u­fac­tur­ing over new price pres­sure

A service from the Financial Times